Share ownership Regeneron Pharmaceuticals, Inc.

REGN

US75886F1075

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-13 pm EDT			5-day change	1st Jan Change
746.46 ^USD	-0.32%		-2.02%	-3.29%

Apr. 13	Regeneron Pharmaceuticals, Inc. and Telix Pharmaceuticals Limited Announce Strategic Radiopharma Collaboration	CI
Apr. 13	Regeneron, Telix Enter Radiopharma Collaboration; Telix Shares Up Pre-Bell	MT

Share class: Regeneron Pharmaceuticals, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	10	1,817,146	0	0	77.36 %
Stock B	1	135,707,536	106,383,352 ( 78.39 %)	28,200,000 ( 20.78 %)

Major shareholders: Regeneron Pharmaceuticals, Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 8.734 %	9,075,153	8.734 %	7 012 M $
BlackRock Advisors LLC 6.204 %	6,446,180	6.204 %	4 981 M $
STATE STREET CORPORATION 4.486 %	4,660,808	4.486 %	3 601 M $
Dodge & Cox 4.424 %	4,596,358	4.424 %	3 551 M $
JPMorgan Investment Management, Inc. 3.792 %	3,940,160	3.792 %	3 044 M $
Fiduciary Trust Company International 2.464 %	2,560,004	2.464 %	1 978 M $
Geode Capital Management LLC 2.425 %	2,519,540	2.425 %	1 947 M $
Fidelity Management & Research Co. LLC 2.232 %	2,319,566	2.232 %	1 792 M $
BlackRock Life Ltd. 1.998 %	2,076,181	1.998 %	1 604 M $
Teachers Advisors LLC 1.935 %	2,010,517	1.935 %	1 553 M $
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Leonard Schleifer 82.56 %	1,725,565	82.56 %	1 333 M $
George Yancopoulos 2.045 %	42,750	2.045 %	33 M $
Fineco Asset Management DAC 1.295 %	27,060	1.295 %	21 M $
Mercer Global Investments Europe Ltd. 0.2861 %	5,979	0.2861 %	5 M $
BG Fund Management Luxembourg SA 0.2782 %	5,815	0.2782 %	4 M $
Ersel Asset Management SGR SpA 0.162 %	3,386	0.162 %	3 M $
Quaestio Capital Management SGR SpA 0.003301 %	69	0.003301 %	53 312 $
Mackenzie Investments Corp. (United States) 0.000383 %	8	0.000383 %	6 181 $

Breakdown by shareholder type

Institutional	69.88%
Other	10.82%
State Street Corp.	4.49%
Individuals	3.76%
Manulife Financial Corp.	0.41%
Schweizerische Nationalbank	0.27%
Sumitomo Mitsui Trust Group, Inc.	0.27%
Swedbank AB	0.22%
Polar Capital Holdings Plc	0.2%
Governments	0.15%
The Bank of Nova Scotia	0.12%
SEI Investments Co.	0.1%
Danske Bank A/S	0.1%
Skandinaviska Enskilda Banken AB	0.05%
ING Groep NV	0.05%
Zurich Insurance Group AG	0.04%
Banco Bilbao Vizcaya Argentaria SA	0.03%
Univest Financial Corp.	0.02%
Fifth Third Bancorp	0.01%
The Allstate Corp.	0.01%
Ledyard Financial Group, Inc.	0.01%
Unknown	8.99%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	65.23%
United Kingdom	8.78%
Individuals	3.76%
Canada	3.25%
France	1.52%
Norway	1.4%
Switzerland	0.91%
Japan	0.8%
Australia	0.72%
Sweden	0.72%
Netherlands	0.59%
Luxembourg	0.51%
Germany	0.44%
South Korea	0.41%
Hong Kong	0.39%
Denmark	0.36%
Ireland	0.31%
Spain	0.15%
China	0.12%
Belgium	0.1%
Austria	0.1%
Singapore	0.08%
Finland	0.08%
Italy	0.07%
Mexico	0.05%
New Zealand	0.04%
Czech Republic	0.03%
Puerto Rico	0.02%
India	0.01%
Taiwan	0.01%
South Africa	0.01%
Poland	0.01%
Liechtenstein	0.01%
Slovenia	0.01%
Israel	0.01%

Based on 1000 largest holdings

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.

Employees

15,410

Sector

Pharmaceuticals

Calendar

Apr. 29 - Earnings release - Q1 2026

More about the company